The filing itself is routine compensation. The key catalyst is the FDA decision on ONS-5010 due by July 31 — the cash bonuses are a direct signal management expects a favorable ruling. Monitor for the FDA action; a positive decision would be a major catalyst, while a negative one removes the bonus trigger and is bearish.
Price Chart
Executive Summary
Outlook Therapeutics granted stock options to its CEO (100,000 options) and CFO (210,078 options) at $1.4304/share, vesting in July 2027, and approved cash bonuses of $420,000 (CEO) and $200,000 (CFO) contingent on FDA approval of ONS-5010 by July 31, 2026. This is a routine compensatory arrangement tied to the BLA process, not a departure or material change in leadership, and carries no immediate financial impact for shareholders beyond the potential cash payout if the FDA milestone is met within days.
Key Facts
- CEO Robert C. Jahr received 100,000 stock options at $1.4304/share, vesting July 21, 2027.
- CFO Lawrence A. Kenyon received 210,078 stock options at $1.4304/share, vesting July 21, 2027.
- CEO awarded a cash bonus opportunity of $420,000, payable only if FDA approves ONS-5010 by July 31, 2026.
- CFO awarded a cash bonus opportunity of $200,000, payable only if FDA approves ONS-5010 by July 31, 2026.
- Bonuses are contingent on FDA approval of ONS-5010 (bevacizumab-vikg) by July 31, 2026, and continued service through payment date.
- Options granted under the 2024 Equity Incentive Plan in recognition of 2025 and 2026 BLA efforts.
Financial Impact
Up to $620,000 in cash bonuses contingent on FDA approval by July 31, 2026; option grants have no immediate cash impact.
Risk Factors
- FDA may not approve ONS-5010 by July 31, 2026, rendering bonuses unearned.
- Stock price remains near $1.43, with Nasdaq minimum bid price compliance risk noted in the recent DEFA14A.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-086406 |
| Document: 0001104659-26-086406-index-headers.html | 0001104659-26-086406 |
| Document: 0001104659-26-086406-index.html | 0001104659-26-086406 |
| Document: 0001104659-26-086406.txt | 0001104659-26-086406 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access